Exhibit (d)(2)
![]() | Mutual Confidentiality Agreement KalVista Pharmaceuticals Inc. and Chiesi Farmaceutici S.p.A. | ||
MUTUAL CONFIDENTIALITY AGREEMENT
This Mutual Confidentiality Agreement (the “Agreement”) is made on the 23rd day of January, 2026 (the “Effective Date”), between
KalVista Pharmaceuticals, Inc., a Delaware corporation having an address of 55 Cambridge Pkwy Cambridge, MA 02142 (“KalVista”); and
Chiesi Farmaceutici S.p.A. having its place of business at Via Palermo, 26/A, 43122 Parma, Italy (“Counterparty”).
KalVista and Counterparty may be referred to individually as a “Party” and together as the “Parties.”
RECITALS
WHEREAS the Parties intend to exchange Confidential Information (as defined below) for KalVista related to its business, technology, and know-how in the area of rare diseases with unmet medical needs including Hereditary Angioedema, and for Counterparty related to its business, technology and know-how in relation to rare diseases field for the purpose of evaluating a potential business relationship or transaction (the “Purpose”).
WHEREAS the Parties wish to protect and preserve the confidential and/or proprietary nature of the Confidential Information that may be disclosed by a Party (the “Disclosing Party”) to the other Party (the “Receiving Party”).
1 | Definitions |
1.1 | “Affiliate” means any entity, person, corporation, company, partnership, now or in the future, controlling, controlled by, or in common control with a Party. For the purposes of this definition, “control” means ownership, directly or indirectly, of at least fifty percent (50%) of voting rights in an entity, or rights or powers to control the management of such entity, corporation, company, partnership, or in the case of an unincorporated entity, of person exercising similar functions. |
1.2 | “Confidential Information” means any and all information, data and materials, including without limitation, information regarding research, development, service offerings, new and existing products, marketing and selling plans, business plans, budgets and unpublished financial statements, distribution arrangements, prices and costs, suppliers and customers, trade secrets, know-how, goodwill, techniques and designs, the existence of any business discussions, negotiations or agreements between the Parties, and any information regarding the skills and compensation of employees, contractors or agents of the Disclosing Party, and any information regarding the Disclosing Party’s rights pertaining to copyright, patent, patent applications, drawings, discoveries, intentions, improvements, technical data, formulae, computer programs, trademarks, logos, registered and unregistered designs, design rights, and similar industrial or intellectual property rights, disclosed by the Disclosing Party to the Receiving Party for the Purpose whether oral (provided that data and information disclosed orally are confirmed in writing by the Disclosing Party within 30 (thirty) days after the date of such disclosure), in writing or in electronic form and whether or not identified by the Disclosing Party as confidential or proprietary or which may be reasonably presumed to be so at the time of disclosure, the existence of this Agreement and the terms and conditions of this Agreement, and the fact that the Parties carry out the discussion, negotiation, evaluation and assessment for the Purpose. In this Section 1.2, any references to the Disclosing Party will be deemed a reference to the Disclosing Party or its Affiliates. |
2 | Obligations of Confidentiality |
2.1 | The Receiving Party will treat all Confidential Information disclosed by the Disclosing Party or its Affiliates in the strictest confidence. The Receiving Party will not use the Confidential Information for any purpose except for the Purpose. The Receiving Party will not, directly or indirectly, disclose or attempt to disclose, the Confidential Information to any person or legal entity who is not a party to this Agreement (except in in accordance with Section 2.2 below). |
